VIRULENT ONCOLYTIC HERPES SIMPLEX VIRUS STRAINS ENGINEERED TO COUNTER THE INNATE HOST RESPONSE

• US 20110236415A1
• Filed: 04/27/2010
• Published: 09/29/2011
• Est. Priority Date: 06/24/2004
• Status: Active Grant

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Mohr, Ian, Mulvey, Matthew
• Granted Patent: US 8,252,277 B2
• Time in Patent Office: Days
• US Class Current: 424/199.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 35/763 Herpes virus
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16661 Methods of inactivation or attenuation
• CPC Class Codes: C12N 2710/16662 by genetic engineering
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ₁34.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

Claims

1-18. -18. (canceled)

19. A method of immunizing a subject against an infectious disease, cancer, or an autoimmune disease, said method comprising:

administering to a subject a modified herpes simplex virus under conditions effective to immunize the subject against an infectious disease, cancer, or an autoimmune disease,

wherein the modified herpes simplex virus has an intact U_s12 gene and an endogenous U_s11 gene expressed as a late gene, and is modified from a wild-type herpes simplex virus with both γ

₁34.5 genes of the virus being deleted and U_s11 genes that are expressed as immediate-early (IE) genes being inserted in the γ

₁34.5 gene locus in place of both γ

₁34.5 genes.

20. The method of claim 19 wherein the U_s11 genes are under control of a herpes simplex virus IE promoter.

21. The method of claim 19, wherein the promoter is an α

27 IE promoter.

22. The method of claim 19, wherein the modified herpes simplex virus further comprises an ICP 6-inactivating mutation.

23. The method of claim 19, wherein the wild-type herpes simplex virus is herpes simplex virus type 1 (HSV-1).

24. The method of claim 23, wherein the HSV-1 is a strain selected from the group consisting of HSV-1 strain 17, strain KOS, strain F, strain Patton, and any clinical isolate thereof.

25. The method of claim 19, wherein the wild-type herpes simplex virus is herpes simplex virus type 2 (HSV-2).

26. The method of claim 25, wherein the HSV-2 is a strain selected from the group consisting of HSV-2 strain G, strain HG52 and any clinical isolate thereof.

27. The method of claim 19, wherein the modified herpes simplex virus is administered by injection, infusion instillation or inhalation.

28. The method of claim 19, wherein the subject is a mammal.

29. The method of claim 28, wherein the mammal is a human.